Macrocure to Host and Webcast Analyst & Investor Day on February 12, 2015

Company to Provide Comprehensive Review of Mechanism of Action Study Results and Patient Case Studies

Five Physicians to Present and Host Question and Answer Session

PETACH TIKVA, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that it will be hosting and webcasting its Analyst & Investor Day on Thursday, February 12, 2015, in New York City. Nissim Mashiach, President and CEO, Michael Molyneaux, Chief Medical Officer, other members of Macrocure's senior management team and Key Opinion Leaders from the wound care industry will present and participate in a question and answer session. The event and live webcast will begin at 2:00 p.m. Eastern Time and is scheduled to conclude at 5:00 p.m. Eastern Time.

The objective of the event is to provide a comprehensive overview of the Company's Mechanism of Action (MOA) study, present patient and physician case studies, and review the wound care market and the science and technology behind CureXcell™.

Presentations will highlight the impact of CureXcell on angiogenesis, cell proliferation, extracellular matrix and tissue maturation. The event will detail CureXcell's MOA using a state-of-art model and additionally, provide insight into the underlying cell biology, which validates CureXcell as a bona fide regenerative tissue repair technology.

The following Key Opinion Leaders will be attending and presenting:

  • Robert Kirsner, MD, PhD, Professor, Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine
  • William Li, MD, President and Medical Director, The Angiogenesis Foundation
  • Ram Sack, MD, Orthopedic Department, Gali Medical Center, Nahariya, Israel
  • Robert Snyder, DPM, MSc, CWS, FACFAS, Past President, Association for the Advancement of Wound Care, Professor and Director of Clinical Research, School of Podiatric Medicine, Barry University, Miami
  • Jeremy Tamir, MD, Advanced Wound Care/Plastic Surgery, Wichita, Kansas. Formerly, Sheba Medical Center-Plastic Surgery Department, Tel Aviv, Israel

"CureXcell has the potential to change the treatment paradigm for healing of chronic and hard-to-heal wounds. This event will provide a quantitative and qualitative overview of CureXcell that describes how this promising technology works. The identity of growth and regenerative factors and their effects will be disclosed," stated Dr. Wiliam Li, President and Medical Director, The Angiogenesis Foundation.

"I have worked with Macrocure's CureXcell for over 10 years. I am very excited that the MOA results support and validate the outstanding clinic results I have seen in the past. I look forward to sharing my experience during this event and conveying my enthusiasm for this 'game-changing technology'," shared Jeremy Tamir, MD, Advanced Wound Care/Plastic Surgery, Wichita, Kansas.

Attendance and Participation

In-person attendance will be by invitation only. Interested parties can listen to the live webcast, view the presentation slides and submit questions by visiting the Investor Relations section of the Company's website at under 'Events & Presentations'. To register for the webcast please visit: Alternatively, for a listen-only telephonic broadcast, participants may dial (877) 407-9221 (domestic/U.S.) or (201) 689-8597 (international). The webcast will be archived on the Company's website.

About Macrocure Ltd.

Founded in 2008, Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.

About CureXcell

Macrocure's lead product candidate, CureXcell, is a unique combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. CureXcell is currently in two pivotal, Phase III, double-blind clinical trials targeting a broad indication for the treatment of all types of wounds below the knee. For more information, please visit:

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACT: Francesca DeMartino Investor Relations & Corporate Communications +1 (310) 739-6476